IKT News and Press, Inhibikase Therapeutics Inc. From 01/25/23

Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules PR Newswire BOSTON and ATLANTA , Jan. 25, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IK...

Inhibikase Therapeutics ( NASDAQ: IKT ) stock rose ~12% on Wednesday after the company said that the U.S. Food and Drug Administration (FDA) lifted a clinical hold on IkT-148009 in Parkinson's disease (PD). In November, the FDA had placed a clinical hold on the company's IkT-1...

Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders PR Newswire - Animal model studies highlight potential of the c-Abl inhibitor IkT-148009 to modify the course of Parkins...

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease PR Newswire - Phase 2a '201' clinical trial will resume immediately at 50 and 100 mg doses- -Additional safety and pharmacokinetic information will be measured ...

Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro PR Newswire BOSTON and ATLANTA , Dec. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-...

Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs PR Newswire BOSTON and ATLANTA , Dec. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical comp...

Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference PR Newswire BOSTON and ATLANTA , Nov. 22, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company develop...

Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Conference Call November 15, 2022 8:00 AM ET Company Participants Alex Lobo – Stern Investor Relations Milton Werner – President and Chief Executive Officer Conference Call Participants ...

Inhibikase Therapeutics press release ( NASDAQ: IKT ): Q3 GAAP EPS of -$0.18. Revenue of $0.007M (vs. $0.33M Y/Y). Cash, cash equivalents and marketable securities were $26.5M as of September 30, 2022. For further details see: Inhibikase Therapeutics GAAP EPS...

Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity PR Newswire Company to host conference call and webcast on November 15, 2022 at 8:00am ET BOSTON and ATLANTA , Nov. 14, 2022 /PR...